- Healthcare Professionals
- Research
- Clinical trials
- TELIX Prostac study
2025-03-01T00:00:00.000+00:00
Ongoing
TELIX Prostac study
TELIX Prostac study
Chronic Lymphocytic Leukaemia
A multinational, multicenter, prospective, randomized, controlled, open-label, phase 3 study of lutetium-177 rosopatamab tetraxetan plus standard of care versus standard of care alone for patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with androgen receptor pathway inhibition.
A multinational, multicenter, prospective, randomized, controlled, open-label, phase 3 study of lutetium-177 rosopatamab tetraxetan plus standard of care versus standard of care alone for patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with androgen receptor pathway inhibition.
Trial overview
Disease
Prostate cancer
Topic
Interventional
Sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Description
A multinational, multicenter, prospective, randomized, controlled, open-label, phase 3 study of lutetium-177 rosopatamab tetraxetan plus standard of care versus standard of care alone for patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with androgen receptor pathway inhibition.
Study details
Trial status
Opening Spring 2025
Principal Investigator
